N6-methyladenosine: a novel therapeutic lever in Alzheimers pathogenesis

In the context of continuous social development and overnutrition, Alzheimer's disease, as a neurodegenerative disease, is becoming more and more common in the elderly and gradually younger, and there is currently no effective treatment. This article reviews the role of m6A as a target site forthe treatment of Alzheimer's disease, discusses the main case characteristics of AD, including tau hyperphosphorylation, neuroinflammation, etc., and discusses the combination of m6A regulation and anti-A/antitau drugs, m6A and anti-inflammatory treatment, etc., and reveals the new mechanism of AD pathogenesis after combining recent related research cases, and proposes that m6A can be used as a new target for AD, providing a new epitranscriptional perspective for the treatment of AD. In addition, it will promote the development of m6A-targeted drugs and provide relevant suggestions to solve the current treatment bottleneck.